55 results
6-K
EX-99.1
SLN
Silence Therapeutics Plc
16 May 24
Current report (foreign)
2:21pm
assets at amortized cost
R&D tax credit receivable
Other current assets
Trade receivables
Non-current liabilities
Contract liabilities
Lease … ) in contract liabilities
Cash spent on operations
Tax paid
R&D tax credits received
Net cash outflow from operating activities
Cash flow from investing
6-K
EX-99.1
SLN
Silence Therapeutics Plc
23 Feb 24
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca
8:12am
, Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca.
Silence and AstraZeneca initiated a multi-target collaboration
6-K
EX-99.1
SLN
Silence Therapeutics Plc
14 Nov 23
Current report (foreign)
12:00am
at amortized cost
R&D tax credit receivable
Other current assets
Trade receivables
Non-current liabilities
Contract liabilities
Lease liability
Current … liabilities
Cash spent on operations
Tax paid
R&D tax credits received
Net cash outflow from operating activities
Cash flow from investing activities
Redemption
6-K/A
EX-99.1
SLN
Silence Therapeutics Plc
29 Aug 23
Current report (foreign) (amended)
4:01pm
assets
Financial assets at amortized cost
Current assets
Cash and cash equivalents
Financial assets at amortized cost
R&D tax credit receivable
Other … Receivable
Increase/(Decrease) in trade and other payables
(Decrease) in contract liabilities
Cash spent on operations
R&D tax credits received
Net
6-K
EX-99.1
io7u2
16 Aug 23
Current report (foreign)
7:00am
S-8
rl9gxn
1 Aug 23
Registration of securities for employees
4:31pm
6-K
EX-99.1
i3t t3n1du
16 May 23
Current report (foreign)
4:01pm
6-K
EX-99.1
ao6iv
4 May 23
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
7:41am
6-K
EX-99.1
ypaniapeg2in8mnc
10 Nov 22
Current report (foreign)
8:30am
6-K
EX-99.1
74fov9wjcjeofvt1
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am
6-K
EX-99.1
1wi43nj
11 Aug 22
6-K Q2 2022 Quarterly Results
5:02pm
6-K
EX-99.1
nl75da02pbzcus0di1
16 May 22
Current report (foreign)
8:31am
6-K
EX-99.1
jmk s0b9qbo
4 Apr 22
Current report (foreign)
8:31am
6-K
EX-99.1
ctyn597k6d83v8 we07
9 Feb 22
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study
7:30am
6-K
EX-99.1
yyw 7cqog
16 Nov 21
Current report (foreign)
6:03am
6-K
EX-99.1
ynkjfdfix88ft 3a19
21 Oct 21
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
8:45am
6-K
t0rik484 b1
21 Oct 21
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
8:45am